Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216690 · ClinicalTrials.gov registry record · Phase 2
Pregnenolone as a Treatment for Cannabis Intoxication
A Phase 2 study, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT07216690: Recruiting Phase 2 study, sponsored by Johns Hopkins University.
NCT07216690 is a Phase 2 study that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07216690, a Phase 2 study, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The present study will characterize the ability of pregnenolone to reverse the acute intoxication and associated symptoms of cannabis. Healthy adults with a history of cannabis use will be recruited to participate in a placebo-controlled, within-subject crossover study at Johns Hopkins Behavioral Pharmacology Research Unit (BPRU). By clarifying the ability of pregnenolone to reverse cannabis intoxication symptoms, this study will pave the way for larger clinical studies that provide a foundation for the development of future CB1-receptor NAM medications that could be applied in emergency situations and potentially validate pregnenolone as a treatment for cannabis intoxication.
Interventions
- DRUG Placebo
- DRUG Cannabis
- DRUG Pregnenolone 250 mg
- DRUG Pregnenolone 500 mg
- DRUG Placebo brownie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-04-24 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07216690
The ClinicalTrials.gov registry entry for NCT07216690 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT07216690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07216690 about?
NCT07216690 is a clinical study titled "Pregnenolone as a Treatment for Cannabis Intoxication". The present study will characterize the ability of pregnenolone to reverse the acute intoxication and associated symptoms of cannabis. Healthy adults with a history of cannabis use will be recruited to participate in a placebo-controlled, within-subject crossover study at Johns Hopkins Behavioral Ph...
What is the current status of trial NCT07216690?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-04-24. Estimated completion is 2029-01-01.
What interventions are being tested in trial NCT07216690?
The interventions under investigation include: Placebo (DRUG), Cannabis (DRUG), Pregnenolone 250 mg (DRUG), Pregnenolone 500 mg (DRUG), Placebo brownie (DRUG).
Who is sponsoring clinical trial NCT07216690?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.